3rd Quarter - Report

AMERICAN SOCIETY OF CONSULTANT PHARMACISTS for AMERICAN SOCIETY OF CONSULTANT PHARMACISTS

Firm
Client
Income
—
Expenses
$40,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Pharmacy Lock-in (s.1913, S.524), Pharmacy provider status (H.R. 592/S.314),

LobbyistCovered position, as disclosed
PETER RANKIN Director of Policy and Advocacy

Contacted: Food & Drug Administration (FDA); Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 1913 (114th), S. 524 (114th), S. 314 (114th), H.R. 592 (114th)

Medicare/Medicaid MMM

HR592/S314 Pharmacy and Medically Underserved Areas Enhancement Act,

LobbyistCovered position, as disclosed
PETER RANKIN —

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 592 (114th)

Pharmacy PHA

H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act, Impact Act Implementation, Repackaging and compounding guidance, controlled substances act requirements for electronic e-kits.

LobbyistCovered position, as disclosed
PETER RANKIN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Drug Enforcement Administration (DEA); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Bills named: S. 314 (114th), H.R. 592 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.